# Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

> **NCT06930859** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 2766 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Letrozole
- **DRUG:** Anastrozole

## Key facts

- **NCT ID:** NCT06930859
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-22
- **Primary completion:** 2032-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 2766 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06930859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06930859, "Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT06930859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*